Trial · NCT02109939
Results by group19
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 19 of 19
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in the 17-item Hamilton Depression (HAM-D17) Score From Baseline to 8 Weeks | Treatment As Usual | -24.39 | Standard Error 1.22 | percentage of change | |
| Percent Change in the 17-item Hamilton Depression (HAM-D17) Score From Baseline to 8 Weeks | GeneSight Psychotropic Tested | -27.23 | Standard Error 1.27 | percentage of change | |
| Percent Change in the 16-item Quick Inventory of Depression Symptomology (QIDS-C16) Score From Baseline to 8 Weeks | GeneSight Psychotropic Tested | -35.107 | Standard Error 1.189 | percentage of change | |
| Percent Change in the 16-item Quick Inventory of Depression Symptomology (QIDS-C16) Score From Baseline to 8 Weeks | Treatment As Usual | -32.900 | Standard Error 1.147 | percentage of change | |
| Percentage of Responders at Week 8 for HAM-D17 | GeneSight Psychotropic Tested | 26.00 | percentage of subjects | ||
| Percentage of Responders at Week 8 for HAM-D17 | Treatment As Usual | 19.92 | percentage of subjects | ||
| Percentage of Remitters at Week 8 Defined as HAM-D17 ≤7 Each Treatment Group; | GeneSight Psychotropic Tested | 15.30 | percentage of subjects | ||
| Percentage of Remitters at Week 8 Defined as HAM-D17 ≤7 Each Treatment Group; | Treatment As Usual | 10.08 | percentage of subjects | ||
| Percent Change in the 17-item Hamilton Depression (HAM-D17) Score From Baseline to 24 Weeks | GeneSight Psychotropic Tested | 42.5 | Standard Error 1.52 | percentage of change | |
| Percentage of Responders at Week 8 for QIDS-C16 | GeneSight Psychotropic Tested | 34.14 | percentage of subjects | ||
| Percentage of Responders at Week 8 for QIDS-C16 | Treatment As Usual | 31.36 | percentage of subjects | ||
| Percentage of Responders at Week 8 for PHQ-9 | Treatment As Usual | 31.63 | percentage of subjects | ||
| Percentage of Responders at Week 8 for PHQ-9 | GeneSight Psychotropic Tested | 39.74 | percentage of subjects | ||
| Percentage of Remitters at Week 8 Defined as QIDS-C16 ≤ 5 in Each Treatment Group | Treatment As Usual | 15.62 | percentage of subjects | ||
| Percentage of Remitters at Week 8 Defined as QIDS-C16 ≤ 5 in Each Treatment Group | GeneSight Psychotropic Tested | 20.89 | percentage of subjects | ||
| Percentage of Remitters at Week 8 Defined as PHQ-9 <5 in Each Treatment Group | Treatment As Usual | 14.79 | percentage of subjects | ||
| Percentage of Remitters at Week 8 Defined as PHQ-9 <5 in Each Treatment Group | GeneSight Psychotropic Tested | 18.58 | percentage of subjects | ||
| Percentage of Responders at Week 24 for HAM-D17 in the GeneSight Psychotropic Tested Treatment Group | GeneSight Psychotropic Tested | 44.3 | percentage of subjects | ||
| Percentage of Remitters at Week 24 Defined as HAM-D17 ≤7 in the GeneSight Psychotropic Tested Treatment Group | GeneSight Psychotropic Tested | 31.1 | percentage of subjects |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02109939/results